Sunshine Biopharma (SBFM) Total Debt (2014 - 2021)

Sunshine Biopharma's Total Debt history runs 8 years deep, the most recent figure standing at $1.9 million for Q4 2021.

• Quarterly Total Debt rose 100.21% year-over-year to $1.9 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.9 million (up 100.21% YoY) and the FY2021 annual result came in at $1.9 million, up 100.21% from the prior year.
• Total Debt was $1.9 million for Q4 2021 at Sunshine Biopharma, down from $3.2 million in the prior quarter.
• Across five years, Total Debt topped out at $3.2 million in Q3 2021 and bottomed at $27541.0 in Q3 2019.
• A 5-year average of $896640.6 and a median of $353467.5 in 2019 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2019 — Total Debt sank 91.19% — and 2021, when it soared 3148.59%.
• Sunshine Biopharma's Total Debt stood at $596577.0 in 2017, then plunged by 47.92% to $310718.0 in 2018, then plunged by 91.14% to $27541.0 in 2019, then soared by 3345.79% to $949006.0 in 2020, then jumped by 100.21% to $1.9 million in 2021.
• Business Quant data shows SBFM's Total Debt at $1.9 million in Q4 2021, $3.2 million in Q3 2021, and $2.1 million in Q2 2021.